an productive you, and Robert, everyone. good eventful XXXX. We had and afternoon, Thank
HERX-negative clinical breast patients X gedatolisib. primary goal HR-positive our enrollment progressed disease after with is This cancer, a trial enrolling year our CDKX/X VIKTORIA-X for was the candidate, begin for advanced treatment trial with Phase to of Our whose lead inhibitor.
FDA U.S. receive the continents clinical to feedback, participate clinical trial feedback We selection finalize began Once then we five we on in finalized Medicines sites the and Agency trial and over XXX European across this of the to study. working 'XX our our protocol completed with protocol.
These very study leading cancer pleased sites patient of some include we breast quarter, After December. the were this our institutions. dose activating the world's to formally third in the past first
the dosing be equivalents from placement, tranche $XX VIKTORIA-X placement $XXX The the of the in triggered loan to the a clinical private of XXXX. the with are Proceeds million the private combined million company's current term sufficient December. a debt in expected securities marketable of current drawdown first operating to plan closing cash through Celcuity's facility patient fund and trial and and cash,
subgroup activity by for So guidance we the subgroup expect prior are the be half of our of far, remain first with 'XX. encouraged trial data VIKTORIA-X data second and half at patient and to patient available in the 'XX, PIKXCA PIKXCA to our sites. for track the be the available to mutated non-mutated We very on continue in
The the on scientific study was launching rationale predicated two key for VIKTORIA-X factors.
prior survival benefit. options unmet significant progression-free HERX-negative modest Current therapeutic cancer a for only better CDKX/X offer for who patients second-line options HR-positive need breast there's therapeutic received First, inhibitors.
combined a Phase only PFS And data study therapies for offer letrozole Xb mutations. plus second, evaluated either lacking PIKXCA promising or they fulvestrant we very our approved with indicate two to median for months. palbociclib of that reported gedatolisib four Published second-line patients results from
of seven therapies approved mutations months. for For publish patients who approximately have data PIKXCA PFS to is median
additional data for arms. in data off four to from Symposium initially results very subgroups December. results. presentation favorably a follow-up, months included PIKXCA since compares broken according to Updates poster XXXX presented in these efficacy Cancer updated and the each we the patient The expansion reported our of we of Breast at efficacy Antonio mutation San in spotlight status We've in Phase published reflect study data our XXXX clinical Xb this XX to
the wild-type For ORR the patients Xb objective those of Phase was schedule are X data These rate XX%. who PIKXCA months response favorably for patients drug published fulvestrant, for the of in was our percentage XX wild-type in Phase study. study, the received gedatolisib, VIKTORIA-X Arm patients to compare D of dosing very the PIKXCA the progression-free patients who results in or control XX% and at
of response PFS a study, for randomized of rate In fulvestrant an recent XX-month XX% reported rate and a X% objective fulvestrant.
patients For response averaged fulvestrant XX%. In rate a for PIKXCA XX-month response alpelisib published the very objective XX%. clinical was regimen, and patients control for PIKXCA-mutated the for the fulvestrant compare the VIKTORIA-X XX-month in rate the alpelisib Again, results the these trials, study. PFS was had averaged who XX% the two and and rate to mutations, PFS rate plus objective D favorably Arm XX%, results
The comparable two by, in believe, is key in rate XX-month effective PFS we PIKXCA patient and factors. wild-type rates subgroups driven mutated response the
of driver PIKXCA First, isoform breast And resistance and biologically PIKX the PIXK optimal tumor because PIXK approach required is inhibiting class four cross or whether in avoids inhibitors. mTOR or patient's with and mutation to the the can subunits mTOR efficaciously specific inactivating has mTOR that regardless pathway mutations second, activation of the not. or two I mTOR complexes address pathway the activity. HR-positive cancer PIKXCA is a occur specific resulting the uninhibited is most it This drug isoforms,
seeking need inhibition to fulvestrant cancer Gedatolisib's last treatment and therapies mechanism for equipotent PANPXKMT in role decision potential designation Breakthrough in address as believe Completely we we an FDA's action to of gedatolisib this targeted the combination HR-positive with of and breast CDKX/X palbociclib differentiated data unmet breast advanced year Therapy inhibitor. suits synergistic a to blockading We in uniquely This the for cancer. to played the believe are other address with the inhibitors. also pathway such need as effective second-line grant the the enhances key July more to HERX-negative induce therapies.
and from median study was rate escalation the months objective compare Median objective arm for efficacy very our treatment combined reported first-line of XX had with rate gedatolisib advanced encouraged treatment. In XX.X results received A These expansion favorably Xb combined as We of the in XX.X arm PFS treatment-naive the A, response results response plus the palbociclib for for was prior were in and patients who the and to also the palbociclib very letrozole and letrozole. disease. received not group months These PALOMA-X study XX% PFS updated patients by patients Phase XX%.
median expansion alone patients XX reached combined updated meeting the not that cancer ESMO in the of as Of as for the and we the May. PFS treatment-naive arms data breast for patients as at data note -- RMA expansion data for efficacy well RMA present is cutoff, with will was June the two
results role HERX-negative These the as data cancer. of develop also provide highlights driver the demonstration a The to the another advanced opportunity plays HR potential pathway PIXK/mTOR option. positive treatment intrinsic disease as breast in a first-line gedatolisib
valuation gedatolisib to practical this While letrozole data combined warrants time, in palbociclib a future. at the a us pursue study plus with promising randomized this for is certainly not first-line evaluating
trials to to for view and potential of studies inhibitors. Another the characterize in new for different in and PIXK types. begin AKT pathways tumor was XXXX linked prioritizing pathway, the inhibitors important We activity evaluation mTOR mTOR conducted indications This to of PIXK goal other us other gedatolisib. of includes evaluating PIXK/mTOR for and previous nonclinical gedatolisib in assessment other
cascade and to and in an breast the reciprocal characterized significant This crosstalk of the multiple and in pathway recurrence signaling plays in cancers prostate feedback progression mTOR literature role cancer. and body signaling addition has XK essential A types. between hormonal in interaction gynecological disease tumor loops PIXK
the loops that cross focus been types, and of approach has led promising on isoforms, in to uninhibited PIXK feedback mTOR strategy, This as demonstrated unmet hormonal in gynecological needs nonclinical research various and cancers. is mTOR the as AKT us co-targeting initial PIXK confounded pathways, and prostate subunits. the is and feed forward our tumor AKT As the well breast between considerations treatment but cancer, a by literature review activate studies
We Society mutation tumor. spare at and cancer February studies, We've PIXK/mTOR PIXK/mTOR drug presented Genitourinary pathway Symposium. most Cancer results first can in which focused more inhibit one the components American how how or Oncology 'XX our weekly selectively enable inhibitors Clinical results a from discussed patient's the -- the key on of previously this on depending status prostate or of resistance
is demonstrated no limited tumors. only it In efficacy PTEN clinical or AKT cancer gene Inhibitors that single prostate in deficient PIXK/mTOR have efficacy target to is frequently and in linked cancer, PTEN muted. and wild-type prostate component PIXK PTEN the a
required. inhibition this cancer, suggests been PIXK/mTOR has As with pathway be that of comprehensive the found may more breast
models. pan-PIXK/mTOR the PTEN-deficient PIXK-AKT-mTOR gedatolisib cancer hypothesis, cancer PTEN positive and their with would inhibitors wild-type sensitivity both cell PTEN this status prostate With different as infected of To assess one component a be gedatolisib at evaluated of other that target for we inhibitor and pathway. lines this least in six to a panel prostate
supportive our hypothesis. from The very encouraging of results these were studies and
was inhibitor PTEN-mutated cells. wild and type efficacious cancer PTEN assessments prostate Our confirm as in was the that only gedatolisib that potent as
assessment, AKT to evaluated. gedatolisib signaling, every superior DNA or In of PIXK, exhibited inhibitors included cell addition, the mTOR which relative potency, and other replication cytotoxicity, in activity all death,
it was been cancer wild-type our Capivasertib. inferior evaluated and gedatolisib. reported only cells less clinical PTEN Capivasertib these Pan-PSK found cancer in A drugs from modest and than much the and Capivasertib the and contrast to in has between trials, the active potent less Capivasertib The and results particular wild-type prostate date gedatolisib note PTEN-mutated with consistent with tumors. clinical PTEN in was efficacy results. in but no are generally the PTEN-mutated tumors nonclinical to inhibitor, has efficacy studies We AKT tenfold
results of blockading PIXK/mTOR of selectively pathway. provide than and we've contract the further these believe the comprehensively demonstration got the gedatolisib rather We importance
gedatolisib three To insensitive In that prostate the models. XX% no vivo inhibition, PTEN tumor models, we xenograft androgen evaluated mylenograft as different models and gedatolisib dovitinib. prostate in We growth more cancer, assess induced evaluated receptor cancer single gedatolisib wild-type PTEN-loss activity than gedatolisib in activity. first dovitinib were whereas agent had inhibitor to both in a in and
was prostate was inhibition as induced also a dovitinib. agent growth XXX% it with this gedatolisib XX% when inhibition dovitinib. a evaluated that cancer We tumor xeonograft model, sensitive In model and combined single to
set XX next the our results We for through clinical in Orlando, from Annual Association Florida from of the is which being will Meeting, held studies Research American Cancer present XX. at April
week. all which evaluate. relative evaluated of inhibitors. exhibited with of the panel activity superior models, last prostate line in studies gynecological PIXK-AKT-mTOR other a summarizing published this several gedatolisib our Consistent inhibitors cancer, to PIXK-AKT-mTOR These abstract cell was data gedatolisib in other findings An
a was these results non-clinical there from these to of action studies significant in PK/PD on for mechanism and the us differentiated opportunity gedatolisib types. we on profile, tumor highly Based internal develop gedatolisib's and think
will on We an development year. clinical provide update our later this priorities
at side would to Now to business Celcuity's the platform. our I diagnostic shift of diagnostics centers third-generation CELsignia, on like discussion our
As you HERX selected the impacted were pathway may FACT-X CELsignia in up recall, our HERX by as CELsignia early FACT-X evaluating patients enrolling delays detected -- is trials that These early-stage diagnostic enrollment are with trials using XXXX. breast now COVID-XX-related during early-stage our cancer breast through whose signaling with patients test. and hyperactive are the cancer
therapy. of Our diagnostic, so their goal the companies to targeted receive number companion eligible as CELsignia can to patients provide that a test is expand pharmaceutical
We these in the XXXX. expect from to second announce half studies of interim results
review I call our With turn to CFO, now Vicky over Hahne, our will that, financial results. to our
